Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

6533b85bfe1ef96bd12bacbc

RESEARCH PRODUCT

Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

Carmela Rodríguez-lópez Patricia Mondelo-macía Teresa Curiel Antònia Obrador-hevia Laura Muinelo-romay Laura Valiña Silvia Calabuig-fariñas Roberto Díaz-peña Rafael López-lópez Angel Diaz-lagares Aitor Azkárate ÓScar Rapado-gonzález María Mercedes Suárez-cunqueiro Luis León-mateos Ihab Abdulkader Alicia Abalo Jorge García-gonzález Santiago Aguín

subject

0301 basic medicine Oncology Male <i>MET</i> copy number medicine.medical_treatment proteínas protooncogénicas c-met dosificación génica humanos resistencia a medicamentos Drug Resistance Gene Dosage circulating free DNA (cfDNA)<i>MET</i> amplification Targeted therapy Targeted therapy 0302 clinical medicine Circulating tumor cell estudios prospectivos Neoplasms antineoplásicos Prospective Studies lcsh:QH301-705.5 Circulating tumor cells (CTCs)neoplasias General Medicine Proto-Oncogene Proteins c-met targeted therapy Neoplastic Cells Circulating ErbB Receptors Cell-free fetal DNA 030220 oncology & carcinogenesis inhibidores de proteína cinasas Biomarker (medicine)Female MET protein expression Cell-Free Nucleic Acids MET amplification medicine.medical_specialty circulating tumor cells (CTCs)estudios de casos y controles Met amplification Circulating free DNA (cfDNA)Antineoplastic Agents Article 03 medical and health sciences Internal medicine medicine Biomarkers Tumor Humans Liquid biopsy Protein Kinase Inhibitors Retrospective Studies business.industry Head and neck cancer estudios retrospectivos Liquid Biopsy Cancer medicine.disease 030104 developmental biology lcsh:Biology (General)Drug Resistance Neoplasm Case-Control Studies MET copy number business

description

MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed MET amplification in circulating free DNA (cfDNA) from 174 patients with cancer and 49 healthy controls and demonstrated the accuracy of the analysis to detect its alteration in patients. Importantly, a significant correlation between cfDNA concentration and MET copy number (CN) in cancer patients (r = 0.57, p &lt

year	journal	country	edition	language
2020-02-01	Cells

10.3390/cells9020522 http://europepmc.org/articles/PMC7072825